4.84 USD
-0.26 (-5.1%)
Overall NTRB gets a fundamental rating of 4 out of 10. We evaluated NTRB against 191 industry peers in the Pharmaceuticals industry. While NTRB seems to be doing ok healthwise, there are quite some concerns on its profitability. NTRB is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
NTRB had negative earnings in the past year.
In the past year NTRB has reported a negative cash flow from operations.
NTRB had negative earnings in each of the past 5 years.
In the past 5 years NTRB always reported negative operating cash flow.
1.2 Ratios
NTRB's Return On Assets of -315.26% is on the low side compared to the rest of the industry. NTRB is outperformed by 94.24% of its industry peers.
With a Return On Equity value of -377.72%, NTRB is not doing good in the industry: 78.53% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -315.26% | ||
| ROE | -377.72% | ||
| ROIC | N/A |
ROA(3y)-86.9%
ROA(5y)-68.06%
ROE(3y)-100.18%
ROE(5y)-79.11%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 34.36%, NTRB is in line with its industry, outperforming 58.12% of the companies in the same industry.
NTRB's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for NTRB so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 34.36% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5YN/A
2. Health
2.1 Basic Checks
NTRB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NTRB has been increased compared to 1 year ago.
NTRB has more shares outstanding than it did 5 years ago.
NTRB has a better debt/assets ratio than last year.
2.2 Solvency
NTRB has an Altman-Z score of 14.87. This indicates that NTRB is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of NTRB (14.87) is better than 85.86% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that NTRB is not too dependend on debt financing.
The Debt to Equity ratio of NTRB (0.01) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 14.87 |
ROIC/WACCN/A
WACC9.42%
2.3 Liquidity
A Current Ratio of 4.78 indicates that NTRB has no problem at all paying its short term obligations.
NTRB's Current ratio of 4.78 is fine compared to the rest of the industry. NTRB outperforms 63.87% of its industry peers.
A Quick Ratio of 4.70 indicates that NTRB has no problem at all paying its short term obligations.
NTRB's Quick ratio of 4.70 is fine compared to the rest of the industry. NTRB outperforms 65.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.78 | ||
| Quick Ratio | 4.7 |
3. Growth
3.1 Past
NTRB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -255.00%.
NTRB shows a strong growth in Revenue. In the last year, the Revenue has grown by 42.93%.
The Revenue has been growing by 41.99% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-255%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1276.65%
Revenue 1Y (TTM)42.93%
Revenue growth 3Y14.58%
Revenue growth 5Y41.99%
Sales Q2Q%40.47%
3.2 Future
The Earnings Per Share is expected to grow by 100.83% on average over the next years. This is a very strong growth
Based on estimates for the next years, NTRB will show a very strong growth in Revenue. The Revenue will grow by 334.01% on average per year.
EPS Next Y-933.33%
EPS Next 2Y110.16%
EPS Next 3Y100.83%
EPS Next 5YN/A
Revenue Next Year23.72%
Revenue Next 2Y557.52%
Revenue Next 3Y334.01%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
NTRB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
NTRB is valuated cheaply with a Price/Forward Earnings ratio of 3.27.
97.91% of the companies in the same industry are more expensive than NTRB, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.78, NTRB is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 3.27 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
NTRB's earnings are expected to grow with 100.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y110.16%
EPS Next 3Y100.83%
5. Dividend
5.1 Amount
No dividends for NTRB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:NTRB (12/15/2025, 4:24:01 PM)
4.84
-0.26 (-5.1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners3.11%
Inst Owner Change7.47%
Ins Owners55.75%
Ins Owner Change0%
Market Cap58.23M
Revenue(TTM)2.58M
Net Income(TTM)-32.08M
Analysts82.86
Price Target15.3 (216.12%)
Short Float %4.6%
Short Ratio4.94
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)11.33%
Min EPS beat(2)-3.81%
Max EPS beat(2)26.47%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-7.55%
Min Revenue beat(2)-13.5%
Max Revenue beat(2)-1.6%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1021.05%
EPS NY rev (1m)-1007.14%
EPS NY rev (3m)-1007.14%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.9%
Revenue NY rev (1m)-80.3%
Revenue NY rev (3m)-80.3%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 3.27 | ||
| P/S | 22.59 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 6.86 | ||
| P/tB | 8.9 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.87
EYN/A
EPS(NY)1.48
Fwd EY30.56%
FCF(TTM)-0.41
FCFYN/A
OCF(TTM)-0.41
OCFYN/A
SpS0.21
BVpS0.71
TBVpS0.54
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -315.26% | ||
| ROE | -377.72% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 34.36% | ||
| FCFM | N/A |
ROA(3y)-86.9%
ROA(5y)-68.06%
ROE(3y)-100.18%
ROE(5y)-79.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5YN/A
F-Score4
Asset Turnover0.25
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 20.01% | ||
| Cap/Sales | 2.02% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.78 | ||
| Quick Ratio | 4.7 | ||
| Altman-Z | 14.87 |
F-Score4
WACC9.42%
ROIC/WACCN/A
Cap/Depr(3y)24.77%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.53%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-255%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1276.65%
EPS Next Y-933.33%
EPS Next 2Y110.16%
EPS Next 3Y100.83%
EPS Next 5YN/A
Revenue 1Y (TTM)42.93%
Revenue growth 3Y14.58%
Revenue growth 5Y41.99%
Sales Q2Q%40.47%
Revenue Next Year23.72%
Revenue Next 2Y557.52%
Revenue Next 3Y334.01%
Revenue Next 5YN/A
EBIT growth 1Y-7.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-60.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-59.09%
OCF growth 3YN/A
OCF growth 5YN/A
NUTRIBAND INC / NTRB FAQ
Can you provide the ChartMill fundamental rating for NUTRIBAND INC?
ChartMill assigns a fundamental rating of 4 / 10 to NTRB.
What is the valuation status of NUTRIBAND INC (NTRB) stock?
ChartMill assigns a valuation rating of 3 / 10 to NUTRIBAND INC (NTRB). This can be considered as Overvalued.
Can you provide the profitability details for NUTRIBAND INC?
NUTRIBAND INC (NTRB) has a profitability rating of 1 / 10.
How financially healthy is NUTRIBAND INC?
The financial health rating of NUTRIBAND INC (NTRB) is 5 / 10.
What is the expected EPS growth for NUTRIBAND INC (NTRB) stock?
The Earnings per Share (EPS) of NUTRIBAND INC (NTRB) is expected to decline by -933.33% in the next year.